BioNexus Gene Lab Corp (NASDAQ: BGLC)

BioNexus Gene Lab Corp is a Wyoming based holding company that conducts business through two wholly owned subsidiaries. Chemrex Corporation Sdn. Bhd. engages in the wholesale of chemical raw materials for industrial manufacturers across Southeast Asia. MRNA Scientific Sdn. Bhd. develops and provides non invasive blood based tests for the early detection of disease biomarkers. The company’s operations are focused on the distribution of fiber reinforced polymer products and the delivery of RNA based diagnostic services. It serves customers in Malaysia Indonesia Vietnam and other Southeast Asian nations for its chemical business while its diagnostic activities are centered in Malaysia with plans for regional expansion.

The company generates revenue from two primary sources. First Chemrex sells fiber reinforced polymer resins and related additives to manufacturers who use them to produce items such as handrails bench tops automotive parts and cleanroom panels. Revenue is derived from product sales with pricing influenced by volume discounts obtained from suppliers. Second MRNA Scientific earns fees for conducting blood sample analyses that assess risk for eleven health conditions including various cancers inflammatory bowel diseases osteoarthritis and cardiovascular risks. Patients or healthcare providers pay per test and the company also offers volume based rebates to hospitals and clinics.

The company operates through the following segments.

• Chemrex segment focuses on the wholesale distribution of fiber reinforced polymer products. It purchases resins such as polyester resin from domestic and international manufacturers and sells them to manufacturers in Malaysia Indonesia Vietnam and other Southeast Asian countries. The product portfolio includes general purpose resins and specialized grades used in pultrusion and other fabrication processes. The segment provides technical assistance pricing advantages and a broad product range to help customers develop new products.

• MRNA Scientific segment develops and markets non invasive blood based tests that detect RNA biomarkers associated with eleven diseases. It operates laboratories in Kuala Lumpur and Penang where blood samples are processed using proprietary gene chip technology and analytical software. The service delivers risk reports to healthcare professionals who use the results to guide further diagnosis and treatment planning. Revenue is generated per test with discounts available for high volume users.

In the chemical raw material market Chemrex holds an estimated twenty percent share of the domestic Malaysian market and about two percent of the broader Southeast Asian market. Its main competitors in Malaysia include Kaliba Sdn. Bhd. Myeast Sdn. Bhd. and RP Product Sdn. Bhd. which offer similar fiberglass reinforced materials. Chemrex differentiates itself through technical expertise from its chemists and engineers volume based purchasing power a wide product catalogue and a one stop sourcing model. In the diagnostic arena MRNA Scientific claims to be the only commercial molecular laboratory in Malaysia offering RNA based testing for cancer inflammatory bowel disease and osteoarthritis. Its competitive advantages stem from the low invasive nature of blood draws the ability to detect disease before symptoms appear and the focus on measuring current risk rather than lifetime risk.

Chemrex serves a diverse group of manufacturers in Southeast Asia with its top five customers accounting for roughly thirty percent of its revenue in fiscal year 2024. These customers are identified only by letters A through E in the filing and represent established firms in the region. MRNA Scientific’s clientele consists of healthcare providers hospitals laboratories and corporate entities that seek employee wellness screening. The company works with twenty seven sample collection centers twelve located in the Klang Valley and fifteen public hospitals and labs nationwide. It also has agreements with corporate clients in Kuala Lumpur to test employees for the panel of eleven diseases.